Contribution of NIH funding to new drug approvals 2010-2016

Abstract This work examines the contribution of NIH funding to published research associated with 210 New Molecular Entities (NMEs) approved by the FDA from 2010-2016. We identified >2 million publications in PubMed related to the 210 NMEs (n=131,092) or their 151 known biological targets (n=1,966,281). Of these, >600,000 (29%) were associated with NIH-funded Projects in RePORTER. This funding included >200,000 Fiscal Years of NIH Project support (1985-2016) and Project Costs >$100 billion (2000-2016), representing ~20% of the NIH budget over this period. NIH funding contributed to every one of the NMEs approved from 2010-2016, and was focused primarily on the drug targets, rather than the NMEs themselves. There were 84 first-in-class products approved in this interval, associated with >$74 billion of NIH-funded Projects. The percentage of Fiscal Years of Project funding identified through TARGET searches, but NOT DRUG searches was greater for NMEs discovered through targeted screening than through phenotypic methods (95% versus 82%). For targeted NMEs, funding related to targets preceded funding related to the NMEs, consistent with the expectation that basic research provides validated targets for targeted screening. This analysis, which captures basic research on biological targets, as well as applied research on NMEs, suggests that the NIH contribution to research associated with new drug approvals is greater than previously appreciated, and highlights the risk of reducing federal funding for basic biomedical research.